Today: 2 July 2026
Browse Category

Defense Industry 30 December 2025 - 5 January 2026

Tokyo stocks today: Nikkei starts 2026 higher as TEPCO, chip and defense names lead

Tokyo stocks today: Nikkei starts 2026 higher as TEPCO, chip and defense names lead

Japan’s Nikkei 225, a price-weighted index of blue-chip shares, jumped about 3% on Monday in Tokyo’s first session of 2026 as investors chased chip and defense stocks and looked past U.S. action in Venezuela. “The market turned risk-on as if uncertainties and threats had been removed,” said Kazuaki Shimada, head of research at IwaiCosmo Securities. The Nikkei closed up 3.03% at 51,865, with Tokyo Electric Power leading gainers on a 9.23% surge. Currency traders echoed that appetite for risk and ran with a stronger dollar. The greenback hit two-week highs against the yen and touched 157.295 yen as traders focused on U.S. ISM manufacturing data due Monday and the U.S. non-farm payrolls report due Friday.
5 January 2026
········
Ondas stock jumps after rebrand plan, West Palm Beach HQ shift and fresh defense orders

Ondas stock jumps after rebrand plan, West Palm Beach HQ shift and fresh defense orders

NEW YORK, Jan 2, 2026, 6:37 PM ET — After-hours Shares of Ondas Holdings Inc rose 13.1% to $11.02 in after-hours trading on Friday after the company said it has moved its corporate headquarters to West Palm Beach, Florida, and plans to change its corporate name to Ondas Inc. The stock traded between $9.92 and $11.04 earlier in the day and volume was about 136 million shares. SEC
3 January 2026
··
1 … 9 10 11 12 13 … 18

Stock Market Today

  • Intuitive Surgical Jumps $6.9 Billion Ahead of Q2, Still 30% Off January High
    July 2, 2026, 3:03 PM EDT. Intuitive Surgical (NASDAQ:ISRG) rallied 4.7% to $421.42, picking up about $6.9 billion in market cap on July 2 and narrowing some of the losses from its Jan. 7 top. But shares are still about 30% below the January $603.88 high, keeping the valuation gap at $65.6 billion. ISRG trades at 51 times trailing earnings and a forward P/E of 37.3. Consensus price target is $565, suggesting 34% upside. Q2 results land July 16, with focus on procedure volumes and da Vinci 5 installs. Sector names Boston Scientific, Stryker, and Medtronic all posted gains even as tech-heavy Nasdaq QQQ lost 2.3%.
Go toTop